Friday, 16 October 2026European Markets

SOGECLAIR Stock Went Down By Over 9% So Far On Wednesday

Loading stream...

(vianews) - shares of sogeclair (cac 40: sog.pa) dropped 9.09% to €18.00 at 13:08 est on wednesday, following the last session's downward trend. cac 40 is dropping 0.97% to €7,237.93, after three successive sessions in a row of losses. this seems, up until now, a somewhat negative trend trading session today.

sogeclair's last close was €19.95, 23.27% below its 52-week high of €26.00.

about sogeclair

sogeclair sa provides engineering and production services to the aeronautics, space, civil and military transport in france. it operates through three divisions: aerospace, vehicle, and simulation. the aerospace division engages in the provision of engineering services in aerostructures, cabins, systems, and manufacturing engineering and tooling services; and design and manufacture of complex structural thermoplastic products, additive manufacturing, and cockpit equipment, as well as cabin furniture and mechanism. the vehicle division is involved in the design and production of special civilian and military vehicles, as well as terrestrial drones, multi-mission platforms, and adapting vehicles. the simulation division engages in the design and supply of turnkey simulators; and development of software simulation platforms. sogeclair sa was incorporated in 1986 and is headquartered in blagnac, france.

earnings per share

as for profitability, sogeclair has a trailing twelve months eps of €-4.84.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.11%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, sogeclair's stock is considered to be overbought (>=80).

sales growth

sogeclair's sales growth for the current quarter is 1.4%.

revenue growth

year-on-year quarterly revenue growth grew by 14.3%, now sitting on 129.51m for the twelve trailing months.

volume

today's last reported volume for sogeclair is 6329 which is 2381.96% above its average volume of 255.

more news about sogeclair (sog.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com